<DOC>
	<DOCNO>NCT00219349</DOCNO>
	<brief_summary>The goal pilot study follow : 1 ) To disseminate examine effectiveness manualized , individual , cognitive-behavioral psychotherapy ( CBT ) adult Generalized Anxiety Disorder ( GAD ) , 2 ) test effectiveness augmentation ( addition ) antidepressant therapy participant fully respond CBT , 3 ) examine individual clinical predictor non-response CBT predictor response augmentation antidepressant therapy . A related goal examine maintenance treatment gain obtain CBT alone CBT augmentation antidepressant therapy , twenty-four month follow-up period . This study serve pilot investigation preparation large federally fund study use treatment approach . We hypothesize CBT result remission ( longer GAD ) and/or high endstate functioning ( clinically meaningful improvement ) approximately 40-50 % participant . Further , hypothesize augmentation antidepressant therapy participant fully respond CBT result clinically significant improvement .</brief_summary>
	<brief_title>Cognitive-Behavioral Therapy Escitalopram Generalized Anxiety Disorder ( GAD )</brief_title>
	<detailed_description>This pilot investigation examine effectiveness augment cognitive behavioral therapy ( CBT ) antidepressant pharmacotherapy ( escitalopram [ Lexapro ] ) adult generalize anxiety disorder ( GAD ) fully respond temporally primary trial CBT . A secondary aim study assess maintenance treatment gain make patient response CBT , CBT antidepressant augmentation therapy , two-year follow-up period . CBT empirically support psychotherapy find effective treating GAD approximately 50 percent patient enrol controlled clinical trial . However , substantial proportion ( nearly half ) individual GAD achieve full remission clinically significant improvement cessation CBT . Escitalopram ( Lexapro ) selective serotonin reuptake inhibitor ( SSRI ) antidepressant , show effective treat GAD several large-scale control clinical trial . The Food Drug Administration approve ecitalopram treatment GAD . The propose research plan encompass conduct open clinical trial ( No randomize placebo control ) 14 session manualized individual CBT person meet DSM-IV-TR diagnostic criterion GAD . This study use treatment manual develop Dr. Thomas Borkovec colleague Pennsylvania State University . Participants meet high endstate function criterion and/or achieve remission follow CBT evaluate periodically twenty-four month follow-up phase . Participants meet high endstate function criterion and/or achieve remission follow completion CBT offer entry twelve-week , open-label , flexible-dose trial escitalopram therapy . Participants receive escitalopram therapy evaluate periodically twenty-four month follow-up phase , well . It anticipate patient fully respond CBT show significant increment improvement GAD symptom , CBT posttreatment level , follow pharmacotherapy escitalopram . At present , study GAD population examine additive sequenced effect psychosocial therapy SSRI antidepressant pharmacotherapy . The propose research first step direction may provide evidence support use combine treatment modality CBT partial non-responders .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>1 . Males female age 18 65 ( inclusive ) 2 . Primary DSMIVTR diagnosis Generalized Anxiety Disorder ( GAD ) significant comorbid anxiety disorder CBT GAD appropriate include PTSD , OCD , prominent panic disorder without agoraphobia 3 . A negative urine toxicology , i.e. , urine specimen test positive use drug abuse , use benzodiazepine , previous three week 4 . Penn State Worry Questionnaire score 55 great 5 . Have score equal &gt; 4 ( Moderately Ill ) Clinical Global Impression ( CGI ) Scale ( severity illness item ) GAD 6 . Ability give inform consent 7 . Fluent English 8 . Willingness CognitiveBehavioral Therapy session audiotaped 1 . Patients diagnosis Major Depressive Disorder within 60 day prior clinical interview , patient `` lifetime '' history diagnose one follow disorder : Schizophrenia , Major Depressive Disorder Psychotic Catatonic feature , Bipolar I Affective Disorder , Organic Mental Disease 2 . DSMIV substance abuse dependence within past 6 month ( except nicotine caffeine ) 3 . Active suicidal homicidal ideation , judge serious suicide risk 4 . Hamilton Rating Scale Depression score great 20 Screening Baseline evaluation 5 . Any unstable medical neurological condition 6 . Women pregnant lactate 7 . Having receive CBT treatment GAD previously 8 . Concurrent psychosocial therapy 9 . Current psychotropic medication exception zolpidem h insomnia 10 . History nonresponse adequate trial escitalopram intolerable adverse effect escitalopram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Anxiety Disorders</keyword>
	<keyword>Anxiety Neuroses</keyword>
	<keyword>Behavior Therapy , Cognitive</keyword>
	<keyword>Escitalopram</keyword>
</DOC>